C. J. Richards

1.8k total citations · 1 hit paper
18 papers, 1.2k citations indexed

About

C. J. Richards is a scholar working on Oncology, Biotechnology and Surgery. According to data from OpenAlex, C. J. Richards has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Biotechnology and 4 papers in Surgery. Recurrent topics in C. J. Richards's work include Cancer Research and Treatments (5 papers), Colorectal Cancer Screening and Detection (4 papers) and Colorectal Cancer Surgical Treatments (4 papers). C. J. Richards is often cited by papers focused on Cancer Research and Treatments (5 papers), Colorectal Cancer Screening and Detection (4 papers) and Colorectal Cancer Surgical Treatments (4 papers). C. J. Richards collaborates with scholars based in United Kingdom, Australia and Netherlands. C. J. Richards's co-authors include Gina Brown, Geraint T. Williams, N S Dallimore, A G Radcliffe, Robert G. Newcombe, Michael W. Bourne, Declan Carey, A. Rajesh, Raman Verma and Rakesh Sinha and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and Journal of Crohn s and Colitis.

In The Last Decade

C. J. Richards

18 papers receiving 1.2k citations

Hit Papers

Morphologic Predictors of Lymph Node Status in Rectal Can... 2003 2026 2010 2018 2003 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. J. Richards United Kingdom 8 920 623 430 200 67 18 1.2k
Hiroyoshi Matsuoka Japan 22 627 0.7× 596 1.0× 97 0.2× 224 1.1× 96 1.4× 61 961
J.P. Gérard France 16 479 0.5× 499 0.8× 68 0.2× 223 1.1× 52 0.8× 44 854
Haitao Zhu China 13 520 0.6× 157 0.3× 755 1.8× 170 0.8× 70 1.0× 53 1.0k
L. Caravatta Italy 19 418 0.5× 284 0.5× 226 0.5× 325 1.6× 67 1.0× 71 886
Joost Rothbarth Netherlands 18 446 0.5× 596 1.0× 52 0.1× 94 0.5× 65 1.0× 46 975
Samer Salah Jordan 14 323 0.4× 189 0.3× 90 0.2× 491 2.5× 61 0.9× 59 726
OE Nieweg Netherlands 15 225 0.2× 225 0.4× 294 0.7× 461 2.3× 44 0.7× 26 783
Lucia Di Brina Italy 15 197 0.2× 135 0.2× 286 0.7× 485 2.4× 51 0.8× 45 815
María Gómez Galdón Belgium 14 487 0.5× 225 0.4× 40 0.1× 156 0.8× 122 1.8× 31 732
Koichi Hayano Japan 20 310 0.3× 326 0.5× 510 1.2× 352 1.8× 37 0.6× 83 933

Countries citing papers authored by C. J. Richards

Since Specialization
Citations

This map shows the geographic impact of C. J. Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. J. Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. J. Richards more than expected).

Fields of papers citing papers by C. J. Richards

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. J. Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. J. Richards. The network helps show where C. J. Richards may publish in the future.

Co-authorship network of co-authors of C. J. Richards

This figure shows the co-authorship network connecting the top 25 collaborators of C. J. Richards. A scholar is included among the top collaborators of C. J. Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. J. Richards. C. J. Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Krebs, Matthew, Amy Branson, Shaun Barber, et al.. (2023). Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.. Journal of Clinical Oncology. 41(16_suppl). 8511–8511. 5 indexed citations
2.
Fennell, Dean A., Sean Ewings, Kayleigh Hill, et al.. (2023). Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.. Journal of Clinical Oncology. 41(16_suppl). 8506–8506. 1 indexed citations
3.
Richards, C. J., et al.. (2023). Designing a problem analysis toolkit in the context of humanitarian engineering. Procedia CIRP. 119. 1065–1070. 1 indexed citations
4.
Fennell, Dean A., Amy King, Amy Branson, et al.. (2022). Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy.. Journal of Clinical Oncology. 40(16_suppl). 8560–8560. 1 indexed citations
5.
Fennell, Dean A., Amy King, Seid Mohammed, et al.. (2021). A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.. Journal of Clinical Oncology. 39(15_suppl). 8558–8558. 7 indexed citations
6.
Fennell, Dean A., Angela Casbard, Robin Rudd, et al.. (2021). A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.. Journal of Clinical Oncology. 39(15_suppl). 8507–8507. 20 indexed citations
7.
Fennell, Dean A., Liz Darlison, Peter Wells-Jordan, et al.. (2020). MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.. Journal of Clinical Oncology. 38(15_suppl). 9057–9057. 5 indexed citations
8.
O’Meara, Dominic J., et al.. (2020). P853 Amoebic colitis mimicking inflammatory bowel disease: a report of four cases. Journal of Crohn s and Colitis. 14(Supplement_1). S656–S657. 1 indexed citations
9.
Openshaw, Mark R., C. J. Richards, David S. Guttery, Jacqui Shaw, & Anne Thomas. (2017). The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics. 17(5). 459–470. 9 indexed citations
10.
Evans, B. J. K., et al.. (2017). Geospatial Data as a Service: The GEOGLAM Rangelands and Pasture Productivity Map Experience. 2017. 1 indexed citations
11.
Evans, B. J. K., et al.. (2016). Extending the Common Framework for Earth Observation Data to other Disciplinary Data and Programmatic Access. AGUFM. 2016. 1 indexed citations
12.
Sinha, Rakesh, Raman Verma, A. Rajesh, & C. J. Richards. (2007). Diagnostic value of multidetector row CT in rectal cancer staging: a comparison of multiplanar and axial images with histopathology. Clinical Imaging. 31(2). 146–146. 4 indexed citations
13.
Sinha, Rakesh, Raman Verma, A. Rajesh, & C. J. Richards. (2006). Diagnostic value of multidetector row CT in rectal cancer staging: comparison of multiplanar and axial images with histopathology. Clinical Radiology. 61(11). 924–931. 42 indexed citations
14.
Brown, Gina, C. J. Richards, Michael W. Bourne, et al.. (2003). Morphologic Predictors of Lymph Node Status in Rectal Cancer with Use of High-Spatial-Resolution MR Imaging with Histopathologic Comparison. Radiology. 227(2). 371–377. 587 indexed citations breakdown →
15.
Brown, Gina, C. J. Richards, Robert G. Newcombe, et al.. (1999). Rectal Carcinoma: Thin-Section MR Imaging for Staging in 28 Patients. Radiology. 211(1). 215–222. 335 indexed citations
16.
Wadler, Scott, George Corner, C. J. Richards, et al.. (1997). Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.. PubMed. 57(9). 1769–75. 102 indexed citations
17.
Loh, Chit Sin, et al.. (1996). Bladder Neck Leiomyoma Causing Obstructive Renal Failure. Scandinavian Journal of Urology and Nephrology. 30(6). 495–496. 2 indexed citations
18.
Holmes, David, et al.. (1983). Bladder Training—3 Years On. British Journal of Urology. 55(6). 660–664. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026